Research in contextEvidence before this studyThrombolysis is the sole effective treatment with a Level Ib evidence for the early treatment of acute ischemic stroke (AIS) that can improve clinical outcomes. Unfortunately, the narrow 4·5-h window with thrombolysis restricts the eligibility of patients and the clinical significance of the treatment. The concept of the penumbra describes dynamic hypo-perfused brain tissue with the capacity to recover if perfusion is promoted. Penumbral quantification would contribute to extending the current time window and including more treatable AIS patients. However, because the methodology for quantifying the penumbra is inadequate, an imaging-based selection for thrombolysis beyond 4·5 h has not been established.Added value of this studyBy including global and regional features of the impaired brain region, we developed a multivariable quantification method for penumbral assessment that reflects more information than assessments from previous studies. The predictive model, which combined both clinical and penumbral signatures, demonstrated a sufficiently high discrimination for clinical outcomes. Through combing clinical factors and quantification of impaired brain regions after AIS, the model enabled the identification of patients who may benefit from thrombolysis.Implications of all the available evidenceOur model provides an approach via the penumbral quantification for identifying patients who may benefit from thrombolytic therapy either within or beyond the 4·5-h window. The current results suggest the necessity of combining clinical and radiological characteristics, as opposed to using the time lag from stroke onset alone, for the selection. The application of this model to a validated cohort in this study showed promising results toward selecting patients who may qualify for thrombolysis and benefit from treatment.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Stroke is the second most common cause of death and the leading cause of adult disability worldwide \[[@bb0005]\] and patients with acute ischemic stroke (AIS) may benefit from thrombolysis up to 4·5 h after onset \[[@bb0010]\], while a treatment beyond this time window is associated with an increased risk of mortality \[[@bb0015],[@bb0020]\]. The time window of 4·5 h is derived from large-sample randomized clinical trials \[[@bb0025],[@bb0030]\]. Using imaging guidance to confirm the eligibility of AIS patients for thrombolytic therapy, despite the 4·5-hour time window, has become clinically pertinent. It is of great value to popularize imaging-guided decision-making for the improved management of AIS progress, especially in primary healthcare centers.

Penumbra quantification is critical for improving clinical outcomes and is a promising strategy for extending the treatment time window \[[@bb0025],[@bb0035]\]. As a dynamic process, the penumbra can persist for as long as 48 h after symptom onset \[[@bb0020]\]. Both CT and MR are valuable imaging modalities for assessing the penumbra \[[@bb0040]\]. Although CT is faster and more widely used, MR is potentially superior to CT because of its higher resolution, rapid identification of acute infarction, and sensitivity to intracranial hemorrhage \[[@bb0045],[@bb0050]\]. Several clinical trials, including DEFUSE 2 and EPITHET, have used the MR mismatch criteria to guide patient selection for thrombolysis \[[@bb0055],[@bb0060]\]. However, the clinical conditions and radiological signatures of patients who are most likely to benefit from thrombolysis have not been clarified \[[@bb0065]\]. In addition, most current MR studies rely on qualitative imaging which might lead to weak interpretation of results \[[@bb0070]\]. Furthermore, based on suggestions from previous studies that the location, volume ratio, and perfusion/diffusion features of the penumbra are all critical predictors of clinical outcome \[[@bb0075], [@bb0080], [@bb0085]\]. Therefore, an overall assessment of penumbral profiles might be helpful in determining whether thrombolytic treatment is effective either within or beyond the 4·5-h window.

The goal of this study was to develop and validate an MR-based model for clinical outcomes. We first introduced a short-term clinical assessment of AIS patients to generate clinical labels. Second, quantitative analyses of the global and regional parameters of the ischemic penumbra and core area were performed. The potential baseline clinical and radiological signatures of AIS patients were screened using machine learning methods based on a short-term clinical label. Finally, predictive models were validated in an independent dataset, with both short-term and long-term clinical labels. We hypothesized that these models would help to select patients eligible for thrombolysis and to develop personalized therapy during AIS management.

2. Materials and methods {#s0025}
========================

2.1. Study design {#s0030}
-----------------

In this study, we developed predictive models for AIS patients including two independent datasets which were collected from seven independent hospitals, as listed in Supplementary Table S1. Firstly, the training dataset was retrospectively collected in three hospitals from June 2012 to October 2016. After the training dataset were collected, we used a prospective dataset, which were collected from September 2008 to July 2010 \[[@bb0090]\], to validate our results. The study was approved by the Ethics Committees of all listed hospitals and informed consent was obtained. The study design is shown in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Study design. FCO = favorable clinical outcome; UFCO = unfavorable clinical outcome; DWI = diffusion-weighted imaging; PWI = perfusion-weighted imaging; MN is defined in Eq. [(1.1)](#fo0005){ref-type="disp-formula"}; mRS = modified Rankin scale.Fig. 1

The enrollment criteria were as follows: 1) diagnosis of early stroke; 2) age between 18 and 80 years; 3) absence of contraindications to MRI; 4) absence of brain tumor or pregnancy; 5) absence of intracranial hemorrhage on CT/MRI at baseline; 6) both diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) acquired within 9-hours after AIS onset; 7) intravenous recombinant tissue plasminogen activator (IV-rtPA) treatments or conventional medical treatments after MR scanning; and 8) completion of National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) assessments on Day-7 after onset for the training dataset; or completion of NIHSS on Day-7 and mRS assessments on both Day-7 and Day-90 after onset for the validation dataset.

The exclusion criteria were as follows: 1) poor image quality; 2) perfusion imaging failure; and 3) non-detection of lesion on DWI or PWI.

Certain clinical assessments were performed by experienced neuro-radiologists to record the symptoms at onset. Specific information was obtained from each patient at baseline, namely, age, sex, time lag between onset and baseline MRI scan (T-M), baseline systolic blood pressure (SBP), and diastolic blood pressure (DBP). Additionally, other potential risk factors such as hypertension, diabetes, hyperlipidemia, atrial fibrillation, and previous stroke or transient ischemic attack (TIA) were collected. The radiological analyses had not yet been performed at the time of hospital admission and the decision-making regarding treatment was based on conventional clinical information.

2.2. Clinical assessments {#s0035}
-------------------------

NIHSS and mRS scores on Day-7 were recorded and combined for an early clinical outcome assessment. A combined score (MN) of mRS and NIHSS is defined below (Eq. [(1.1)](#fo0005){ref-type="disp-formula"}) and a favorable clinical outcome (FCO) was defined as MN ≥ 4. Unfavorable clinical outcome (UFCO) was defined as MN \< 4. Furthermore, a long-term clinical label was evaluated on Day-90. Specifically, FCO was defined as mRS \< 2 and UFCO was defined as mRS ≥ 2.$$\mathit{MN} = \Delta\mathit{NIHSS} + \left( {3 - \mathit{mRS}} \right) \ast 4$$

2.3. MR image processing and penumbral quantification {#s0040}
-----------------------------------------------------

DWI and PWI sequences were acquired for all participants. The detailed acquisition parameters are listed in Supplementary Table S2. Pre-processing and statistical analyses of MRI data were carried out using tools from the FMRIB Software Library ([www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl){#ir0005}) \[[@bb0095],[@bb0100]\]. In addition, MATLAB scripts developed in house were used in the preprocessing.

The DWI images were preprocessed as follows: 1) skull stripping on b~0~ imaging; 2) calculation of the ADC maps; and 3) estimation of a rigid transformation from the individual space to the MNI152 standard brain (FNIRT in FSL, 2 mm isotropic). The PWI images were preprocessed as follows: 1) detection of the baseline image; 2) alignment of each volume to the baseline image; 3) smoothing of the 4D images using a 6-mm FWHM Gaussian kernel; 4) estimation of a rigid transformation from the perfusion baseline images to the DWI image space; and 5) generation of a linear transformation between the individual space to the MNI152 template (FNIRT in FSL, 2 mm isotropic). The perfusion image calculation was based on a standard singular value decomposition model \[[@bb0105]\], including cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT) and Tmax.

Before applying mismatch, all maps were transferred and resampled to b~0~ (DWI space), resampling with a 2-mm voxel size. The quantitative penumbral analysis was conducted with the following steps. Firstly, the brain mask (see [Fig. 3](#f0015){ref-type="fig"}b) was generated and applied to all calculated maps in the DWI space. Second, penumbral segmentation was performed based on a mismatch model \[[@bb0110],[@bb0115]\]. Thirdly, with a clustering filter, any cluster \<9 voxels (72 mm^3^) was excluded from the final results. Finally, the penumbral identification was reconstructed into 3-dimensional visualization \[[@bb0120]\] and the results are shown in [Fig. S1](#f0030){ref-type="graphic"}. In comparison with the traditional 2D demonstration of penumbral identification, a 3D reconstruction model clearly showed a jagged interlocking pattern of the penumbra. After image preprocessing and penumbral identification, the images were reviewed by two radiologists (Y.C. and D.L.Z.).

Meanwhile, the cortex labels, as shown in [Fig. S2](#f0035){ref-type="graphic"}, were transferred to the native space to identify the positions of the ischemic penumbra and core area based on the invert transfer matrix (See [Fig. 3](#f0015){ref-type="fig"}b, labeled maps). The labeled atlas was based on the MNI space (MNI-maxprob-thr0-2 mm.nii.gz). After merging the thalamus, caudate, putamen, pallidum, hippocampus, amygdala, and accumbens into one area, the gray matter of the brain was divided into six separate regions and labeled accordingly, as shown in [Fig. S2](#f0035){ref-type="graphic"}. Along with the white matter area, the whole brain was divided into seven local regions for further analysis. In addition, a group of three parameters (volume ratio, ADC and CBF) within each separate region was defined as the regional features, and the penumbra and core area were separately calculated for each group. The value of the intact brain region was replaced with the mean value of the region. For regional quantification, 42 features from the seven separate regions were extracted and are listed in Table S3.

MIS was defined to quantify the ischemic penumbra and defected area of AIS patients (Eq. [(1.2)](#fo0010){ref-type="disp-formula"}). The volumes of the core area were defined by DWI defected area volume, and the volumes of penumbra were defined by PWI defected with intact DWI maps. V~PWI~ represented the volume of PWI defected areas, V~PWI~ represented the volume of DWI defected areas and V~MIX~ represented the volume of both the DWI and PWI defected areas.$$\mathit{MIS} = \left( {V_{\mathit{PWI}} - V_{\mathit{DWI}}} \right)/\left( {V_{\mathit{PWI}} + V_{\mathit{DWI}} - V_{\mathit{mix}}} \right)$$

Global ischemic penumbra and core variables including core region volume, penumbral region volume, ADC/CBF of the core region, ADC/CBF value of the penumbra region were quantitatively calculated, as well as 42 regional features of the penumbra and core area (see Supplementary Table S3). The value of the intact brain region was replaced with the mean value of the region.

2.4. Statistical analyses {#s0045}
-------------------------

### 2.4.1. Clinical measurements {#s0050}

SPSS Statistics software (Version 21.0, IBM) was used for the statistical analyses. Two-sample *t*-tests and Pearson\'s correlation analyses were employed and the reported significance levels were all two-sided, with statistical significance set at 0·05. Data are presented as mean \[standard deviation (SD)\], median \[interquartile range (IQR)\], and number (percentage), as appropriate.

### 2.4.2. Feature selection {#s0055}

Based on the short-term clinical labels, the clinical and radiological features were evaluated with a feature selection procedure. In our study, the Least Absolute Shrinkage and Selection Operator method (LASSO) logistic regression model \[[@bb0125]\] was conducted in the training dataset to select the most predictive features for clinical outcome.

To compare the predictive capabilities of the clinical features, MIS and regional features (see Supplementary Table S3), three different models were evaluated as listed below.

Clinical model: The input of this model contained 12 potential variables that were purely clinical, namely, sex, age, baseline SBP, baseline DBP, hypertension, atrial fibrillation, diabetes, hyperlipidemia, previous stroke or TIA, T-M, baseline NIHSS, and treatment option.

Mismatch model: The input of this model covered all 12 potential variables listed in Clinical model plus MIS.

Combined model: The input of this model contained 61 potential variables covering clinical information, global and regional information, including the 12 clinical variables listed in Clinical model, seven global ischemic penumbra and core variables (MIS, core region volume, penumbral region volume, ADC/CBF of the core region, ADC/CBF value of the penumbra region), and 42 regional features of the penumbra and core area (see Supplementary Table S3).

### 2.4.3. Development and validation of the predictive models {#s0060}

Based on the short-term clinical label, the clinical model, mismatch model, and combined model were independently validated. Moreover, the models were further tested with a long-term clinical label which was defined based on mRS scores assessed on Day-90.

The predictive models were developed and validated using WEKA software ([http://www.cs.waikato.ac.nz/ml/weka/](http://www.cs.waikato.ac.nz/ml/weka){#ir0010}). Logistic model tree (LMT) models were developed based on the selected features in the training dataset \[[@bb0130]\]. The performances of the predictive models were evaluated with receiver operating characteristic (ROC) analysis, and pairwise ROC comparisons between our models were tested using Delong method \[[@bb0135]\]. Model calibration was assessed with the Hosmer--Lemeshow goodness-of-fit test \[[@bb0140]\]. To estimate the clinical utility of our models, decision curve analysis was performed by calculating the net benefits for a range of threshold probabilities in the validation dataset.

To avoid algorithm bias, we applied four machine learning methods and used reclassification methods to evaluate the models, the detailed information was list in Supplementary S1. The packages used in R for the discrimination and calibration of the predictive models were also list in Supplementary S1.

3. Results {#s0065}
==========

3.1. Clinical assessment {#s0070}
------------------------

As shown in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"} patients were excluded because of poor image quality, 6 patients were removed because of the failure to acquire a perfusion image, and another 2 patients were excluded because of the absence of lesions on the DWI/PWI maps. Finally, a total of 155 patients were included in the final data analyses, with 84 in the training dataset (age from 43 to 80, 59 males) and the remaining 71 in the validation dataset (age from 36 to 80, 45 males). The mRS scores of the AIS patients are shown in [Fig. 2](#f0010){ref-type="fig"}. For the short-term clinical label, there were 41 patients (48·8%) in the FCO group in the training dataset and 42 patients (59·2%) in the FCO group in the validation dataset. On Day-90, there were 41 patients (57·7%) in the FCO group.Fig. 2Scores on the modified Rankin Scale (mRS) on Day-7 in the training dataset and on Day-7 and Day-90 in the validation dataset. 0, no symptoms; 1, no clinically relevant disability; 2, slight disability (able to look after own affairs without assistance but not to a full extent); 3, moderate disability (requires some help but able to walk unassisted); 4, moderately severe disability (requires assistance and unable to walk unassisted); 5, severe disability (requires constant nursing care); 6, dead.Fig. 2

The characteristics of the AIS patients at baseline are shown in [Table 1](#t0005){ref-type="table"}. Significant differences were evident for SBP and IV-rtPA involvement in both training and validation datasets. Age, Sex, baseline NIHSS score and hyperlipidemia involvement were detected to be significantly different between the FCO group and UFCO group in the training dataset while no difference was found in the validation dataset. In the validation dataset, there were more hypertension patients in the UFCO group than in the FCO group.Table 1Characteristics of the AIS patients at baseline in training and validation datasets.Table 1Training datasetValidation datasetUFCO (*N* = 43)FCO (*N* = 41)*P*-valueUFCO (*N* = 29)FCO (*N* = 42)*P*-valueGeneral clinical informationSex(Male)26 (60·5%)33 (80·5%)0·04421 (72·4%)24 (57·1%)0·187Age,years, median (Range)67 (43--80)66 (47--80)0·04162 (36--80)61·5 (40--77)0·797  Risk factorsHypertension28 (65·1%)28 (68·3%)0·76119 (65·5%)17 (40·5%)0·038Atrial fibrillation10 (23·3%)10 (24·4%)0·9042 (7·0%)8 (19·0%)0·123Diabetes14 (32·6%)9 (22·0%)0·2803 (10·0%)3 (7·0%)0·650Hyperlipidemia3 (7·0%)10 (24·4%)0·0303 (10·0%)7 (17·0%)0·443Previous stroke or TIA6 (14·0%)10 (24·4%)0·2312 (7·0%)4 (10·0%)0·693  Baseline informationT-M (hours)4·39 ± 1·993·60 ± 1·630·0514·54 ± 1·734·50 ± 2·000·931SBP (mmHg)156·65 ± 16·36145·90 ± 21·040·011159·55 ± 21·38143·43 ± 23·170·004DBP (mmHg)88·35 ± 13·7585·15 ± 13·560·28693·41 ± 16·4484·93 ± 15·070·031NIHSS score, median (Range)10 (2--24)6 (1--14)\<0·00110 (4--21)8·5 (4--21)0·104IV--rtPA16 (37·2%)25 (61·0%)0·03010 (34·0%)26 (62·0%)0·023[^2]

3.2. Penumbral quantification {#s0075}
-----------------------------

The quantification results of the penumbra and core area are shown in [Fig. 3](#f0015){ref-type="fig"}. As shown in [Fig. 3](#f0015){ref-type="fig"}b, the penumbra and core area were labeled green and red. The probability of core and penumbral area in all the AIS patients in the training and validation datasets is shown in Supplementary Fig. S3. The relationship between MIS and the clinical assessments MN was investigated on Day-7 are shown in [Fig. 4](#f0020){ref-type="fig"}a. On Day-7, there were significant correlations between MIS and clinical assessments such as NIHSS score, mRS score, MN, and improvement of NIHSS score between baseline and Day-7 in both datasets (see [Table 2](#t0010){ref-type="table"}).Fig. 3Segmentation of the penumbra and core area. (a) Original maps. ADC map, CBF map, CBV map and Tmax map; (b) mask, segmentation and labeled results. The penumbra is shown in green and the core area is shown in red. ADC = Apparent diffusion coefficient; CBF = cerebral blood flow; CBV = cerebral blood volume; DWI = diffusion-weighted imaging; PWI = perfusion-weighted imaging.Fig. 3Fig. 4Scatter plots of the clinical assessments and radiological measurements. (a) Scatter plots of MIS and MN; (b) Scatter plots of the outputs of the combined LMT model and MN; MN is defined in Eq. [(1.1)](#fo0005){ref-type="disp-formula"}; MIS represents quantification of the ratio of ischemic penumbra to the defected area, which is defined in Eq. [(1.2)](#fo0010){ref-type="disp-formula"}; IV--rtPA = Intravenous tissue plasminogen activator; LMT = logistic model tree.Fig. 4Table 2Pearson\'s correlation between the MIS and clinical assessments in the training and validation datasets.Table 2T-MN~0~N~7~mRS~7~mRS~90~MNΔNIHSSTraining datasetPearson\'s correlation−0·308−0·091−0·278−0·360--0·3700·313*P* -value0·0040·4100·0110·001--0·0010·004N84848484--8484Validation datasetPearson\'s correlation−0·1730·179−0·363−0·402−0·2990·5130·528*P*-value0·1500·1350·0020·0010·011\<0·001\<0·001N71717171717171[^3]

3.3. Feature selection and model development {#s0080}
--------------------------------------------

In clinical model, five features survived in the feature selection, namely, sex, baseline SBP, T-M, baseline NIHSS, and the treatment option. In MIS model, four features survived, namely, baseline SBP, baseline NIHSS, treatment option, and MIS. In combined model, seven features survived, namely, baseline SBP, baseline NIHSS, treatment option, MIS, ratio of the core area in the temporal lobe (R.C.T), ADC value in the white matter area of the penumbra (ADC.C.W) and CBF value in the occipital lobe of the penumbra (CBF.P.O).

As shown in [Table 3](#t0015){ref-type="table"}, significant differences were detected in MIS, R.C.T, and CBF.P.O in both datasets, whereas, ADC.C.W was significantly different in the training dataset alone. The predictive models were developed based on LMT and are outlined below. The scatter plots of MN and the output of the combined model of all of our patients are shown in [Fig. 4](#f0020){ref-type="fig"}b.Table 3Radiological characteristics of AIS patients with FCO versus UFCO in the training and validation datasets.Table 3Training datasetValidation datasetFCO (N = 41)UFCO (N = 43)*P*-valueFCO (N = 42)UFCO (N = 29)*P*-valueRadiological characteristics MIS0·800 ± 0·2800·584 ± 0·309\<0·0010·858 ± 0·1500·578 ± 0·3840·001 R.C.T0·146 ± 0·2630·040 ± 0·0640·0330·198 ± 0·2160·113 ± 0·1380·049 ADC.C·W0·615 ± 0·2190·485 ± 0·1520·0010·490 ± 0·1790·513 ± 0·1650·574 CBF.P·O0·162 ± 0·1070·114 ± 0·0660·0060·196 ± 0·0990·144 ± 0·0700·012[^4]

The model calculates the predicted probability of the models as follows:

$$\ P_{C\mathit{linical}} = 4 \cdot 44 - \mathit{Sex}^{\ast}0 \cdot 50 - \mathit{SBP}^{\ast}0 \cdot 02 - T - M^{\ast}0 \cdot 02 - {N_{0}}^{\ast}0 \cdot 12 + \mathit{Treatment}^{\ast}0 \cdot 80$$$$\ P_{\mathit{MIS}} = 2 \cdot 40 - \mathit{SBP}^{\ast}0 \cdot 02 - {N_{0}}^{\ast}0 \cdot 12 + \mathit{Treatment}^{\ast}0 \cdot 74 + \mathit{MIS}^{\ast}1 \cdot 15\ $$$$\begin{array}{r}
{\ P_{C\mathit{ombined}} = 0 \cdot 69 - \mathit{SBP}^{\ast}0 \cdot 01 - {N_{0}}^{\ast}0 \cdot 09 + \mathit{Treatment}^{\ast}0 \cdot 54 + \mathit{MIS}^{\ast}1 \cdot 15\ } \\
{+ R.C.T^{\ast}2 \cdot 61 + \mathit{ADC}.C.W^{\ast}0 \cdot 99 + \mathit{CBF}.P.O^{\ast}2 \cdot 73\ } \\
\end{array}$$

In Eq. [(1.3)](#fo0015){ref-type="disp-formula"}, Sex is defined as 1 with male patients, while 2 with female patients. In Eq. [(1.3)](#fo0015){ref-type="disp-formula"}, [(1.4)](#fo0020){ref-type="disp-formula"}, [(1.5)](#fo0025){ref-type="disp-formula"}, Treatment is defined as 1 with IV-rtPA while Treatment is defined as 0 with conventional medical treatment. In Eq. [(1.3)](#fo0015){ref-type="disp-formula"}, [(1.4)](#fo0020){ref-type="disp-formula"}, [(1.5)](#fo0025){ref-type="disp-formula"}, *N*~0~ is the NIHSS score after onset.

3.4. Model validation {#s0090}
---------------------

The ROC curves of the predictive models are shown in [Fig. 5](#f0025){ref-type="fig"}. Based on the short-term validation, the AUCs of the clinical model, MIS model, and combined model were 0·743 (95% CI: 0·629--0·856), 0·854 (95% CI: 0·767--0·941), and 0·863 (95% CI: 0·774--0·951), respectively. With pairwise ROC comparisons, there are significant differences between clinical model vs mismatch model (*P* = 0·002) and clinical model vs. combined model (*P* = 0·003). There is no significant difference between our two imaging based models: mismatch model and combined model (*P* = 0·749). In addition, we analyzed the predict performance of the combined model of short-term validation in patients with or without IV-rtPA treatments. The AUC in the patients with IV-rtPA is 0·869 (95% CI: 0·739--1·000), while in patients without IV-rtPA is 0·799 (95% CI: 0·636--0·963). The Hosmer--Lemeshow test of model calibration with a non-significant *p* value showed favorable calibration of our models, for short-term models: *P*~*clinical\ model*~ = 0·778; *P*~*mismatch\ model*~ = 0·202; *P*~*combined\ model*~ = 0·450. The decision curves of our models in the validation datasets were shown in [Fig. S4](#f0045){ref-type="graphic"}, indicating the clinical usefulness of our models.

Furthermore, based on the long-term validation, the AUCs of the clinical model, MIS model, and combined model were 0·697 (95% CI: 0·573--0·821), 0·773 (95% CI: 0·662--0·884) and 0·778 (95% CI: 0·668--0·888). In the long-term models, there is significant difference between clinical model vs mismatch model (*P* = 0. 030). There is no significant difference between clinical model vs. combined model (*P* = 0·058) and mismatch model vs. combined model (*P* = 0·870). The Hosmer--Lemeshow test of model calibration with a non-significant p value showed favorable calibration of our models, for long-term models: *P*~*clinical\ model*~ = 0·959; *P*~*mismatch\ model*~ = 0·649; *P*~*combined\ model*~ = 0·437.Fig. 5ROC curves of predictive models. (a) ROC curves of the models in the training dataset; (b) ROC curves of models in the validation dataset, with short-term labels; (c) ROC curves models in the validation dataset, with long-term labels. Black lines indicate the ROCs of the clinical models. Red lines indicate the ROCs of the mismatch models. Green lines indicate the ROCs of the combined models; ROC = Receiver operating characteristics; AUC = area under the curve.Fig. 5

4. Discussion {#s0095}
=============

In this study, predictive models for individual clinical outcome after AIS onset was developed and validated with both short-term and long-term clinical labels. The combined model included both clinical characteristics and advanced MR penumbra profiles derived from machine learning methods. The predictive power of the model was validated using an independent dataset and reached AUCs of 0·863 in the short-term validation and 0·778 in the long-term validation, indicating a favorable discriminative ability.

4.1. Clinical labels {#s0100}
--------------------

To identify the potential features at baseline and to develop predictive models for further clinical outcomes of AIS patients, reasonable clinical labels were needed. It has been shown that the early mRS can serve as a good proxy for Day-90 outcomes \[[@bb0145],[@bb0150]\], suggesting that short-term and long-term clinical assessments had a similar treatment effect magnitude. A combined score was used to generate an early clinical label to discriminate potential clinical and radiological features using machine learning methods. With external validation, this combined score has demonstrated a reasonable ability to distinguish the relative features of AIS patients at baseline.

4.2. Penumbral quantification {#s0105}
-----------------------------

Several early studies reported that DWI/PWI mismatch was correlated with clinical assessments \[[@bb0155],[@bb0160]\]. Consistently, our study found that MIS was significantly correlated with clinical outcomes, suggesting that the penumbra, the main target of salvageable brain tissue, is associated with FCOs with adequate medical care \[[@bb0020]\]. With penumbral imaging, two clinical trials based on diffusion-perfusion were performed to select patients for thrombolysis beyond the current time window, but failed to reach the endpoints \[[@bb0055],[@bb0165]\]. Although the exact reasons for the failure remain unknown, the inadequacy of the penumbral identification methodology may have led to the negative results. Our study aimed to develop a quantitative penumbral method to evaluate the extent of the global penumbral existence and local tissue characteristics. Compared with global signatures, the regional features of the penumbra and core area might capture more information regarding tissue impairment after AIS \[[@bb0080],[@bb0085]\] and may help predict clinical outcomes.

4.3. Predictive model performance {#s0110}
---------------------------------

Three different models were developed in our study, the combined model included both clinical and radiological signatures had the best ability to predict the 3-month clinical outcomes of AIS patients. These results might suggest that with machine learning methods, the regional features of the penumbra and core area are integrated with the clinical factors and treatment option to affect clinical outcome. A recent study developed a multivariable model, including clinical information and CT assessments, to predict clinical outcomes \[[@bb0170]\]. Consistent with our results, SBP, baseline NIHSS, and IV-rtPA treatment were confirmed to be independent predictors of clinical outcomes. In contrast, rather than via visual assessment, the features in our model were derived from machine learning techniques, which included more objective radiological signatures. These favorable results demonstrate that with machine learning techniques, essential clinical and radiological features can be revealed and predictions of clinical outcomes for AIS patients can be more accurately identified than with conventional methods. This interpretation could be supported by the external validation in the independent dataset in our study, which also demonstrated a favorable prediction performance based on the combined model with both short-term and long-term clinical labels.

4.4. Clinical Implications {#s0115}
--------------------------

Although penumbral imaging is already widely acknowledged in clinical practice, penumbral imaging for selecting candidates for thrombolysis has not been validated \[[@bb0175]\]. Several clinical trials, including EPITHET, DIAS II, and MR RESCUE, have failed to confirm the clinical validity of penumbral imaging \[[@bb0055],[@bb0165],[@bb0180]\], largely because of improper penumbral definition. In the current study, our model enabled the prediction of favorable clinical outcome for each individual up to 9 h after stroke onset. By providing a promising strategy in detail to guide current patient selection in AIS management, the application of our models will be particularly meaningful to hospitals that are not competent enough to be qualified for endovascular treatment.

4.5. Limitations {#s0120}
----------------

The main limitation of this study is that the treatment choice was not randomized and there might have been selection bias and information bias. With an independent validation, these biases might have been controlled. However, the observational nature of this study may have still limited the interpretation of current results. Further validations in pre-designed clinical trials are recommended. Second, the sample size was relatively small and imaging protocols for current data varied from one center to another, so the homogeneity of the sample may have been affected. The application of the models to a relatively larger cohort with a prospective design would generate more convincible evidence to guide current patient selection in AIS management.

5. Conclusions {#s0125}
==============

In summary, the proposed imaging-based models contain both clinical and imaging signatures, showing sufficiently high discrimination for clinical outcomes of AIS patients. Despite patient heterogeneity, the model still acquired relatively high AUCs, indicating the robustness and reliability of our methodology. This model may be clinically useful because the model enables patient selection for thrombolysis either within or beyond the 4·5-h time window, especially in hospitals that are not qualified for endovascular treatments.

The following are the supplementary data related to this articleFig. S1Three-dimensional reconstruction of penumbral identification. Note: Core area are shown in red; penumbra are shown in blue; subcortical areas are shown in brown to point out the relative position of the impaired area and the brain; SBP = Systolic blood pressure; DBP = diastolic blood pressure; T-M = time from stroke onset to MRI scan before treatment; IV--rtPA = Intravenous tissue plasminogen activator. NIHSS = National Institutes of Health Stroke Scale; mRS = modified Rankin Scale. (a) Patient 1: 62 years old male; Diabetes; Baseline SBP: 157 mmHg; T-M: 7·0 h; Baseline NIHSS: 18; MIS: 0·94. Conventional medical treatment; Day-7: mRS = 5; NIHSS = 19; (b) Patient 2: 78 years old male; Baseline SBP: 186 mmHg; T-M: 3·5 h; Baseline NIHSS: 15; MIS: 0·63. With IV-rtPA treatment; Day-7: mRS = 5; NIHSS = 15.Fig. S1Fig. S2Location labels of our regional partition of the brain.Fig. S2Fig. S3Lesion maps in training and validation datasets. Note: colour of the overlay demonstrated the T value of one sample *t*-tests within the training or validation dataset with the impaired area.Fig. S3Fig. S4Decision Curves of predictive models. Black lines indicate the decision curve of the clinical model. Red lines indicate the decision curve of the mismatch model. Green lines indicate the decision curve of the combined model; the y axis measures the net benefit; the x-axis represents the probability threshold.Fig. S4Supplementary materialImage 1
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[^2]: Note: Data are presented as mean ± SD or n (%). SBP = systolic blood pressure; DBP = diastolic blood pressure; T-M = time from stroke onset to MRI scan before treatment; IV-rtPA = intravenous tissue plasminogen activator; FCO = favorable clinical outcome; UFCO = unfavorable clinical outcome. FCO and UFCO were defined based on MN on Day-7; MN is defined in Eq. [(1.1)](#fo0005){ref-type="disp-formula"}.

[^3]: Note: MIS represents quantification of the ratio of ischemic penumbra to the defected area, which is defined in Eq. [(1.2)](#fo0010){ref-type="disp-formula"}; T-M = time lag between onset and the baseline MRI scan; NIHSS = National Institutes of Health Stroke Scale; N~0~ = baseline NIHSS score; N~7~ = NIHSS score on Day-7; mRS = modified Rankin Scale; mRS~7~ = mRS score on Day-7; mRS~90~ = mRS score on Day-90; ΔNIHSS = the improvement of NIHSS score between baseline and Day-7.

[^4]: Note: Data are presented as mean ± SD. MIS represents quantification of the ratio of ischemic penumbra to the defected area, which is defined in Eq. [(1.2)](#fo0010){ref-type="disp-formula"}; AIS = acute ischemic stroke; FCO = favorable clinical outcome; UFCO = unfavorable clinical outcome; FCO and UFCO were defined by MN on Day-7; MIS = mismatch ratio; R.C.T = ratio of the core area in the temporal lobe; ADC.C.W = ADC value in the white matter area of the core area; CBF.P.O = CBF value in the occipital lobe of the penumbra.
